PT Diagnos Laboratorium Utama Tbk
IIDX:DGNS298.00
IDR
+36.00
(+13.74%)
ISIN
ID1000158702
Return %
Stock
S&P 500
1Y
104.11
14.20
3Y
9.56
81.12
5Y
-63.44
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Fergus Richard
- Full Time Employees
- 81
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Gedung Graha Anam Lantai 2 Jakarta JK Indonesia 1500358
- IPO Date
- Jan 15, 2021
- Website
- diagnos.co.id
- Similar Companies
- Business
- PT Diagnos Laboratorium Utama Tbk (DGNS.JK) provides laboratory-based health diagnostic services in Indonesia, including clinical pathology testing, anatomical pathology examination, genomics analysis, homecare health checks, and corporate wellness programs; clinical pathology encompasses hematology, hemostasis, clinical chemistry, urinalysis, biomolecular assays, immunology, microbiology; genomics offers non-invasive prenatal testing (NIPT), preimplantation genetic testing for aneuploidy (PGT-A), preimplantation genetic testing for monogenic diseases (PGT-M), reproductive health genetic screening, oncology tests, drug sensitivity profiling, and DNAandMe personal genomics; homecare delivers at-home tests for hemoglobin, ferritin, reticulocytes, routine hematology, SARS-CoV-2 Omicron molecular screening, and PCR; corporate services include tailored medical check-ups (MCU) such as employee health panels for heart, kidney, allergy, cancer risk, and prenatal care bundles. The company operates 11 clinical laboratory locations including RSIA Bunda Jakarta, RSU Bunda Margonda Depok, Diagnos Padang, Diagnos Denpasar, and Diagnos Makassar, primarily serving individual patients, pregnant women, families, corporations, and healthcare providers within the diagnostics and research segment of the healthcare industry. Founded in 2007 and headquartered at Gedung Graha Anam, 2nd Floor, Jl. Cikditiro No. 11 A, B, C, Gondangdia, Menteng, Central Jakarta, DKI Jakarta 10350, Indonesia, Diagnos forms part of the Bundamedik Healthcare System (BMHS), focusing on maternal and child health technologies. In recent developments, the company completed the acquisition of 97.97% of Asa Ren Pte. Ltd., a Singapore-based AI-driven DNA data and biotechnology firm, for approximately IDR 357.89 billion via inbreng of shares and cash purchase, funded partly through a rights issue of 921 million new shares raising IDR 465.10 billion; this strategic move enhances genomics capabilities and introduces AI-biotech synergies. Additionally, Diagnos secured a bank facility from PT Bank Mandiri Tbk in 2024 and partnered with PT PPG Indonesia and PT PPG Coatings for employee medical check-up programs emphasizing occupational health screenings.